Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDKN1A | P38936 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CD38 | P28907 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22060151 | 0.90 | ABCB1 (0.44) | CDKN1APOLBCD38 | |
| SCHEMBL22060181 | 0.85 | CDKN1A (0.44) | CDKN1ANPC1RAB9AMEN1KMT2A | |
| SCHEMBL22060741 | 0.85 | CDKN1A (0.52) | CDKN1ANPC1RAB9AMEN1KMT2A | |
| SCHEMBL22060180 | 0.84 | POLB (0.52) | CDKN1ANPC1RAB9AMEN1KMT2A | |
| SCHEMBL22060178 | 0.83 | CDKN1A (0.49) | CDKN1ANPC1RAB9AALDH1A1MAPT | |
| SCHEMBL22060684 | 0.81 | MAPK1 (0.54) | CDKN1AMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL22060133 | 0.80 | NR3C1 (0.48) | CDKN1ANPC1RAB9ALMNACYP2C9 | |
| SCHEMBL22060343 | 0.80 | KDR (0.45) | CDKN1AMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL22060137 | 0.79 | MAPK1 (0.54) | CDKN1ANPC1RAB9AMEN1KMT2A | |
| SCHEMBL22060182 | 0.78 | POLB (0.49) | CDKN1ANPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | NYSNOBIO IRELAND DAC (IE) | 2021-08-12 | — | — | US | disclosed |
| US-10889553-B2 | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same | NYSNOBIO IRELAND DAC (IE) | 2021-01-12 | — | — | US | disclosed |
| US-20200172497-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | TP53, RB1, CDK1 | CDKN1A 7/4885NPC1 3769/4885RAB9A 2007/4885 |
| US-20200172497-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | ATG7, PINK1, ADRM1 | CDKN1A 594/4885NPC1 1820/4885RAB9A 1771/4885 |
| US-10889553-B2 | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same | ATG7, PINK1, ADRM1 | CDKN1A 594/4885NPC1 1820/4885RAB9A 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.